Foamix Pharmaceuticals Ltd. Announces Closing of Its $69 Million Public Offering of Ordinary Shares

REHOVOT, Israel, and BRIDGEWATER, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced the closing of its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other estimated offering expenses, will be approximately $64.2 million.

Barclays Capital Inc., Cowen and Company, LLC and Guggenheim Securities, LLC acted as book-running managers for the offering. Oppenheimer & Co. Inc. acted as co-manager.

The offering of these securities has been made only by means of a written prospectus. A copy of the prospectus related to the offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1 (888) 603-5847, or by emailing:; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, fax: 631-254-7140; or Guggenheim Securities, LLC, 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, telephone: (212) 518-9349 or by emailing:

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Foamix Pharmaceuticals Ltd.

Foamix is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix's lead product candidate, FMX101 for moderate-to-severe acne, is a novel topical foam formulation of the antibiotic minocycline. Foamix also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

CONTACT: Dov Tamarkin, CEO Foamix Pharmaceuticals Ltd. +972-8-9316233 U.S. Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979

Source:Foamix, Ltd.